Zydus Lifesciences has reported positive results for its drug, Saroglitazar Magnesium, in a global Phase II(b) trial for treating liver disease. While the news marks a scientific win for potential entry into Western markets, investors are currently observing the company's financial performance following a 36% drop in net profit for the first quarter of the 2027 fiscal year.
Zydus Lifesciences announced that its drug, Saroglitazar Magnesium, successfully reached its primary goal in the global Phase II(b) EVIDENCES-X clinical trial. This study focused on Metabolic dysfunction Associated Steatohepatitis, commonly known as MASH, which is a progressive liver disease linked to metabolic issues. The trial, involving 189 participants across the United States, Turkey, and Argentina, showed a 26.5% improvement in resolving liver inflammation compared to a placebo group after 52 weeks.
For investors, this milestone is significant because it validates the drug's efficacy in a international setting. While Saroglitazar Magnesium is already approved for use in India for MASH and related liver conditions, it is still in the experimental stage in the United States and Europe. The company plans to share these findings at upcoming scientific conferences and use the data to advance its regulatory discussions in these large, competitive markets.
However, the clinical success arrives at a time when the company faces financial headwinds. In its financial results for the first quarter of the 2027 fiscal year, Zydus Lifesciences reported a consolidated revenue of ₹8,017 crore, which was a 22% increase compared to the previous year. Despite this growth in sales, net profit fell by 36% to ₹939.8 crore. This gap between rising revenue and falling profit highlights rising operational costs and margin pressure, with the company's EBITDA margin contracting to 24.1% during the quarter.
Developing drugs for the US and European markets involves high capital spending and significant execution risk. Regulatory hurdles, clinical trial requirements, and competition from global pharmaceutical giants can impact the timelines and costs for such projects. Investors may want to balance the optimism regarding the new trial data with the company's current financial reality, specifically looking at whether profit margins improve in the coming quarters.
The next steps for the company will be to present the detailed trial findings to regulators and the scientific community. Investors may watch for updates on when the company files for approvals in the US and Europe, as well as management's commentary on how they plan to control costs and improve profitability to support these research-heavy projects.